Business Context and Reporting Period
Company: Phio Pharmaceuticals Corp. (PHIO)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal Year Ended December 31, 2024
Business Overview: Phio is a clinical-stage biotechnology company developing immuno-oncology therapeutics using its proprietary INTASYL® self-delivering RNAi technology. The company operates as a single segment focused on clinical development. In 2024, the company transitioned from a discovery research model to a product development focus, implementing significant cost rationalization measures, including reducing headcount by over 50% and moving to a primarily remote operational model with a small rented laboratory facility.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(7,150) | $(10,826) |
| Operating Expenses | $7,387 | $10,824 |
| Research & Development (R&D) | $3,643 | $6,332 |
| General & Administrative (G&A) | $3,744 | $4,366 |
| Cash and Cash Equivalents (Year-End) | $5,382 | $8,490 |
| Net Cash Used in Operating Activities | $(7,112) | $(10,749) |
| Net Cash Provided by Financing Activities | $3,996 | $7,413 |
| Stockholders' Equity | $4,723 | $7,730 |
Note: The company has no product revenue and relies on financing activities to fund operations.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 32% ($3.4 million) compared to 2023. R&D expenses dropped 42% due to the wind-down of preclinical studies, reduced headcount, and lower clinical trial fees. G&A expenses decreased 14% primarily due to lower professional fees and D&O insurance premiums.
- Net Loss Improvement: Net loss improved by $3.7 million (34%) year-over-year, driven by the reduction in operating expenses and an increase in interest income ($231k in 2024 vs. $(8k) expense in 2023).
- Financing Activity: The company raised approximately $4.0 million in net proceeds during 2024 through registered direct offerings and warrant inducements. Subsequent to year-end (January 2025), the company raised an additional $6.8 million in net proceeds.
- Collaboration Termination: In May 2024, the company terminated its Clinical Co-Development Agreement with AgonOx, Inc., eliminating future financial obligations for that specific trial while retaining accrued liabilities of approximately $34,000.
- Capital Structure: A 1-for-9 reverse stock split was completed in July 2024. As of December 31, 2024, there were 1,733,717 shares of common stock outstanding.
Guidance, Outlook, and Risks
Clinical Pipeline and Outlook
- PH-762 (Lead Candidate): Currently in a Phase 1b dose-escalating clinical trial for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
- Progress: 7 patients enrolled in cohorts 1 and 2. Safety Monitoring Committee recommended dose escalation in both instances.
- Results: In Cohort 2 (4 patients), 2 achieved complete response (100% tumor clearance), 1 achieved partial response (90% clearance), and 1 had stable disease. No dose-limiting toxicities were observed.
- Timeline: Enrollment of all 30 patients is expected to be completed in Q3 2025.
- PH-894: IND-enabling studies are complete, but the IND submission has been deferred to prioritize PH-762.
Liquidity and Going Concern
The company has reported recurring losses and negative operating cash flows since inception. As of December 31, 2024, cash resources were $5.4 million. Management states that current cash resources may not be sufficient to fund operations for at least the next 12 months. The continuation of the company as a going concern is dependent on raising additional capital through equity or debt offerings.
Key Risks
- Capital Requirements: Substantial additional funding is required to complete R&D activities. Failure to secure financing could force the company to scale back or terminate operations.
- Clinical Development: Product candidates are in early stages; clinical trials may fail, be delayed, or not lead to regulatory approval.
- Nasdaq Listing Compliance: The company must maintain stockholders' equity of at least $2.5 million and a minimum bid price of $1.00 to remain listed on the Nasdaq Capital Market. While currently compliant, future operating losses could threaten this status.
- Intellectual Property: The company relies on patents and licensed technology; failure to maintain these or infringement claims could harm the business.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.4 million cash balance against the projected burn rate for the PH-762 Phase 1b trial completion in Q3 2025.
- Financing Terms: Review the terms of the January 2025 financings (Series G, H, and I warrants) to assess potential dilution and future exercise prices.
- Clinical Data: Monitor the release of full data from the PH-762 Phase 1b trial, specifically the durability of the complete responses observed in Cohort 2.
- Nasdaq Compliance: Track the stock price and stockholders' equity levels to ensure continued compliance with Nasdaq listing standards (minimum $1.00 bid price and $2.5 million equity).
- Going Concern Status: Assess the likelihood of successful future capital raises given the current market environment and the company's history of warrant-based financings.